[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Amgen Inc (AMGN)

Amgen Inc (AMGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 186,687,840
  • Shares Outstanding, K 539,685
  • Annual Sales, $ 36,751 M
  • Annual Income, $ 7,711 M
  • EBIT $ 9,080 M
  • EBITDA $ 15,447 M
  • 60-Month Beta 0.47
  • Price/Sales 5.06
  • Price/Cash Flow 10.20
  • Price/Book 21.45

Options Overview Details

View History
  • Implied Volatility 32.66% (-0.36%)
  • Historical Volatility 19.61%
  • IV Percentile 87%
  • IV Rank 63.91%
  • IV High 39.99% on 05/28/25
  • IV Low 19.66% on 08/15/25
  • Expected Move (DTE 1) 4.98 (1.44%)
  • Put/Call Vol Ratio 2.64
  • Today's Volume 852
  • Volume Avg (30-Day) 4,689
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 93,006
  • Open Int (30-Day) 95,754
  • Expected Range 341.00 to 350.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 36 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $4.75
  • Number of Estimates 11
  • High Estimate $5.19
  • Low Estimate $4.34
  • Prior Year $4.90
  • Growth Rate Est. (year over year) -3.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
335.06 +3.26%
on 04/07/26
359.45 -3.74%
on 04/09/26
-3.79 (-1.08%)
since 03/23/26
3-Month
335.06 +3.26%
on 04/07/26
391.29 -11.58%
on 03/02/26
+1.23 (+0.36%)
since 01/23/26
52-Week
261.43 +32.34%
on 05/14/25
391.29 -11.58%
on 03/02/26
+68.08 (+24.50%)
since 04/23/25

Most Recent Stories

More News
AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER

Organizational Changes Further Emphasize Integration of Biology and Technology

AMGN : 348.75 (+0.82%)
What to Expect From Amgen's Next Quarterly Earnings Report

Amgen is scheduled to report its first-quarter results next week, and analysts expect a single-digit earnings dip.

XLV : 146.26 (-0.08%)
$SPX : 7,124.08 (-0.19%)
AMGN : 348.75 (+0.82%)
2 S&P 500 Stocks Worth Your Attention and 1 We Ignore

2 S&P 500 Stocks Worth Your Attention and 1 We Ignore

DGX : 200.36 (-1.78%)
LRCX : 265.16 (-0.15%)
AMGN : 348.75 (+0.82%)
2 Dow Jones Stocks with Exciting Potential and 1 Facing Headwinds

2 Dow Jones Stocks with Exciting Potential and 1 Facing Headwinds

NKE : 45.07 (-1.34%)
AMGN : 348.75 (+0.82%)
MCD : 304.05 (+1.33%)
2 Reasons to Like AMGN and 1 to Stay Skeptical

2 Reasons to Like AMGN and 1 to Stay Skeptical

AMGN : 348.75 (+0.82%)
AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE

Primary and Key Secondary Endpoints Met

AMGN : 348.75 (+0.82%)
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy

- Collaboration with Amgen to explore the clinical potential of Zai Lab’s DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen’s IMDELLTRA ® ...

ZLAB : 21.71 (-5.07%)
AMGN : 348.75 (+0.82%)
REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS

Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary Prevention

AMGN : 348.75 (+0.82%)
2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds

2 Mega-Cap Stocks to Keep an Eye On and 1 Facing Headwinds

AVGO : 425.32 (+0.63%)
GEV : 1,146.54 (+1.68%)
AMGN : 348.75 (+0.82%)
Biogen Stock: Is BIIB Outperforming the Healthcare Sector?

Biogen has outperformed its sector peers recently, and analysts remain moderately optimistic about the stock’s prospects.

XLV : 146.26 (-0.08%)
AMGN : 348.75 (+0.82%)
BIIB : 188.54 (-0.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Amgen Inc. is the leading biotech companies world wide, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health & nephrology and neuroscience markets. It developed two most successful drugs, Epogen & Neupogen. Amgen successfully launched two...

See More

Key Turning Points

3rd Resistance Point 352.79
2nd Resistance Point 350.23
1st Resistance Point 348.08
Last Price 348.75
1st Support Level 343.37
2nd Support Level 340.81
3rd Support Level 338.66

See More

52-Week High 391.29
Last Price 348.75
Fibonacci 61.8% 341.68
Fibonacci 50% 326.36
Fibonacci 38.2% 311.04
52-Week Low 261.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.